Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 13,012 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 13,012 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $61.95, for a total transaction of $806,093.40. Following the completion of the transaction, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at approximately $4,464,426.75. This represents a 15.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Disc Medicine Stock Performance

Disc Medicine stock opened at $62.45 on Friday. The stock has a market capitalization of $1.86 billion, a P/E ratio of -15.69 and a beta of 0.76. The company’s fifty day moving average price is $61.53 and its 200 day moving average price is $52.06. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.15. Sell-side analysts predict that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Wall Street Analysts Forecast Growth

IRON has been the topic of a number of research reports. Stifel Nicolaus increased their price objective on Disc Medicine from $79.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. Wedbush reiterated an “outperform” rating and set a $83.00 price objective on shares of Disc Medicine in a research note on Monday, December 9th. Jefferies Financial Group began coverage on Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price on the stock. Finally, Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $87.50.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently bought and sold shares of the company. Amalgamated Bank boosted its stake in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine during the second quarter worth $129,000. Quest Partners LLC acquired a new stake in shares of Disc Medicine in the third quarter valued at about $131,000. Finally, Quantbot Technologies LP purchased a new position in shares of Disc Medicine in the third quarter worth about $146,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.